A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors.

lEarly Clinical Studies Group ofEORTC, 2EORTCData Center, ^Pierre Fabre Oncology, ^Centre Oscar Lambret, Lille, France Summary

September 2016

Background: Vinorelbine is an active drug in the treatment of lung and breast cancers and has a favo...

PHASE-I STUDY OF HIGH-DOSE EPIRUBICIN AND VINORELBINE IN PREVIOUSLY UNTREATED NON-SMALL-CELL LUNG-CANCER STAGE IIIB-IV

Bakker, M
Groen, HJM
Smit, EF
Smeets, J
Riggi, M
Postmus, Pieter

December 1995

The aim of the study was to determine the maximum tolerated dose (MTD) for the combination of high-d...

of Gemcitabine, LY2334737, in Human Tumor Xenografts

Efficacyof Low-doseoralmetronomicdosingof Theprodrug
Susan E. Pratt
Sara Durl
Robert L. Shepard
Gregory P. Donoho
James J. Starling
Enaksha R. Wickremsinhe
Everett J. Perkins
Anne H. Dantzig

September 2016

LY2334737, an oral prodrug of gemcitabine, is cleaved in vivo, releasing gemcitabine and valproic ac...

A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.

Kalykaki, A.
Vamvakas, L
Agelaki, Sofia
Kalbakis, K
Vardakis, N
Sfakiotaki, G
Ignatiadis, Michail
Saridaki, Z.
Karampeazis, A
Karabeazis, A
Mavroudis, Dimitris
Georgoulias, Vassilis

January 2006

The study aimed to determine the maximum tolerated doses (MTDs) and identify the dose-limiting toxic...

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

Koolen, Stijn L. W.
Witteveen, Petronella O.
Jansen, Robert S.
Langenberg, Marlies H. G.
Kronemeijer, Roelien H.
Nol, Annemarie
Garcia-Ribas, Ignacio
Callies, Sophie
Benhadji, Karim A.
Slapak, Christopher A.
Beijnen, Jos H.
Voest, Emile E.
Schellens, Jan H. M.

September 2011

Purpose: LY2334737 is an orally available prodrug of gemcitabine. The objective of this study was to...

A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer

Lorusso V.
Crucitta E.
Silvestris N.
Guida M.
Misino A.
Latorre A.
De Lena M.

January 2003

A phase I study was conducted in order to determine the maximum tolerated dose (MTD) and dose-limiti...

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.

Awada, A.
Biganzoli, L.
Cufer, T.
Beex, L.V.A.M.
Lohrisch, C.
Batter, V.
Hamilton, A.
Nooij, M.A.
Piccart, M.

January 2002

Item does not contain fulltextThe aim of this study was to determine the maximum tolerated dose (MTD...

Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: a multicenter phase II study.

Westeel, Virginie
Breton, J. L.
Braun, Daniel
Quoix, E.
Milleron, B.
Debieuvre, D.
Jacoulet, Pascale
Germa, C.
Kayitalire, L.
Depierre, A.

March 2006

International audienceIn this phase II study, gemcitabine and vinorelbine were combined at suboptima...

The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.

A. Morabito
G. Filippelli
S. Palmeri
F. Ferraù
V. Zagonel
D. Gattuso
V. Catalano
B. Capaccetti
V. Franciosi
V. Accurso
F. Scinto
G. Gasparini
CASCINU, Stefano

January 2003

To evaluate the activity and toxicity of gemcitabine and vinorelbine (GemVin), in patients with adva...

Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.

Gkioulbasanis, I
Souglakos, J
Vardakis, N
Kotsakis, A
Saridaki, Z.
Kentepozidis, N
Polyzos, A
Giassas, S
Ignatiadis, Michail
Bozionelou, V
Christophylakis, C
Georgoulias, Vassilis

January 2007

To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTDs) of weekly hi...

Phase i study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

Stuurman, Frederik
Voest, E.E.
Awada, Ahmad
Witteveen, Petronella
Bergeland, T.
Hals, Petter Arnt
Rasch, Wenche
Schellens, Jan J.H.M.
Hendlisz, Alain

August 2013

Summary: CP-4126 is a gemcitabine (2′,2′-difluorodeoxycytidine; dFdC) 5′ elaidic acid ester. The pur...

An open-label phase 1 dose-escalation clinical trial to determine the maximally tolerated dose and dose-limiting toxicities of a single intravenous gemcitabine administration in dogs with advanced solid tumors.

L., Beatrice
R., Finotello
Dacasto, Mauro
U., Bonfanti
Aresu, Luca
V., Leone
S., Pizzoni
T., Furlanello
G., Balestra
C., ROHRER BLEY
L., Marconato

January 2014

Introduction. Gemcitabine is a nucleoside analogue with unique metabolic and mechanistic properties....

Gemcitabine and vinorelbine combination in patients with metastatic breast cancer

Sanal S.M.
Gokmen E.
Karabulut B.
Sezgin C.

January 2002

PubMed ID: 12047474Both gemcitabine and vinorelbine as single agents have significant activity again...

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study

M. E. Cazzaniga
V. Torri
F. Villa
N. Giuntini
F. Riva
A. Zeppellini
D. Cortinovis
P. Bidoli

January 2014

Background. Vinorelbine (VRB) and capecitabine (CAPE) are demonstrated to be active in pretreated me...

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

Tamura, Tomohide
Minami, Hironobu
Yamada, Yasuhide
Yamamoto, Noboru
Shimoyama, Tatsu
Murakami, Haruyasu
Horiike, Atsushi
Fujisaka, Yasuhito
Shinkai, Tetsu
Tahara, Makoto
Kawada, Kenji
Ebi, Hiromichi
Sasaki, Yasutsuna
Jiang, Haiyi
Saijo, Nagahiro

November 2006

IntroductionZD6474 (vandetanib) is an orally available inhibitor of vascular endothelial growth fact...

lEarly Clinical Studies Group ofEORTC, 2EORTCData Center, ^Pierre Fabre Oncology, ^Centre Oscar Lambret, Lille, France Summary

September 2016

Background: Vinorelbine is an active drug in the treatment of lung and breast cancers and has a favo...

PHASE-I STUDY OF HIGH-DOSE EPIRUBICIN AND VINORELBINE IN PREVIOUSLY UNTREATED NON-SMALL-CELL LUNG-CANCER STAGE IIIB-IV

Bakker, M
Groen, HJM
Smit, EF
Smeets, J
Riggi, M
Postmus, Pieter

December 1995

The aim of the study was to determine the maximum tolerated dose (MTD) for the combination of high-d...

of Gemcitabine, LY2334737, in Human Tumor Xenografts

Efficacyof Low-doseoralmetronomicdosingof Theprodrug
Susan E. Pratt
Sara Durl
Robert L. Shepard
Gregory P. Donoho
James J. Starling
Enaksha R. Wickremsinhe
Everett J. Perkins
Anne H. Dantzig

September 2016

LY2334737, an oral prodrug of gemcitabine, is cleaved in vivo, releasing gemcitabine and valproic ac...

A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.

Kalykaki, A.
Vamvakas, L
Agelaki, Sofia
Kalbakis, K
Vardakis, N
Sfakiotaki, G
Ignatiadis, Michail
Saridaki, Z.
Karampeazis, A
Karabeazis, A
Mavroudis, Dimitris
Georgoulias, Vassilis

January 2006

The study aimed to determine the maximum tolerated doses (MTDs) and identify the dose-limiting toxic...

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

Koolen, Stijn L. W.
Witteveen, Petronella O.
Jansen, Robert S.
Langenberg, Marlies H. G.
Kronemeijer, Roelien H.
Nol, Annemarie
Garcia-Ribas, Ignacio
Callies, Sophie
Benhadji, Karim A.
Slapak, Christopher A.
Beijnen, Jos H.
Voest, Emile E.
Schellens, Jan H. M.

September 2011

Purpose: LY2334737 is an orally available prodrug of gemcitabine. The objective of this study was to...

A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer

Lorusso V.
Crucitta E.
Silvestris N.
Guida M.
Misino A.
Latorre A.
De Lena M.

January 2003

A phase I study was conducted in order to determine the maximum tolerated dose (MTD) and dose-limiti...

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.

Awada, A.
Biganzoli, L.
Cufer, T.
Beex, L.V.A.M.
Lohrisch, C.
Batter, V.
Hamilton, A.
Nooij, M.A.
Piccart, M.

January 2002

Item does not contain fulltextThe aim of this study was to determine the maximum tolerated dose (MTD...

Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: a multicenter phase II study.

Westeel, Virginie
Breton, J. L.
Braun, Daniel
Quoix, E.
Milleron, B.
Debieuvre, D.
Jacoulet, Pascale
Germa, C.
Kayitalire, L.
Depierre, A.

March 2006

International audienceIn this phase II study, gemcitabine and vinorelbine were combined at suboptima...

The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.

A. Morabito
G. Filippelli
S. Palmeri
F. Ferraù
V. Zagonel
D. Gattuso
V. Catalano
B. Capaccetti
V. Franciosi
V. Accurso
F. Scinto
G. Gasparini
CASCINU, Stefano

January 2003

To evaluate the activity and toxicity of gemcitabine and vinorelbine (GemVin), in patients with adva...

Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.

Gkioulbasanis, I
Souglakos, J
Vardakis, N
Kotsakis, A
Saridaki, Z.
Kentepozidis, N
Polyzos, A
Giassas, S
Ignatiadis, Michail
Bozionelou, V
Christophylakis, C
Georgoulias, Vassilis

January 2007

To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTDs) of weekly hi...

Phase i study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

Stuurman, Frederik
Voest, E.E.
Awada, Ahmad
Witteveen, Petronella
Bergeland, T.
Hals, Petter Arnt
Rasch, Wenche
Schellens, Jan J.H.M.
Hendlisz, Alain

August 2013

Summary: CP-4126 is a gemcitabine (2′,2′-difluorodeoxycytidine; dFdC) 5′ elaidic acid ester. The pur...

An open-label phase 1 dose-escalation clinical trial to determine the maximally tolerated dose and dose-limiting toxicities of a single intravenous gemcitabine administration in dogs with advanced solid tumors.

L., Beatrice
R., Finotello
Dacasto, Mauro
U., Bonfanti
Aresu, Luca
V., Leone
S., Pizzoni
T., Furlanello
G., Balestra
C., ROHRER BLEY
L., Marconato

January 2014

Introduction. Gemcitabine is a nucleoside analogue with unique metabolic and mechanistic properties....

Gemcitabine and vinorelbine combination in patients with metastatic breast cancer

Sanal S.M.
Gokmen E.
Karabulut B.
Sezgin C.

January 2002

PubMed ID: 12047474Both gemcitabine and vinorelbine as single agents have significant activity again...

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study

M. E. Cazzaniga
V. Torri
F. Villa
N. Giuntini
F. Riva
A. Zeppellini
D. Cortinovis
P. Bidoli

January 2014

Background. Vinorelbine (VRB) and capecitabine (CAPE) are demonstrated to be active in pretreated me...

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

Tamura, Tomohide
Minami, Hironobu
Yamada, Yasuhide
Yamamoto, Noboru
Shimoyama, Tatsu
Murakami, Haruyasu
Horiike, Atsushi
Fujisaka, Yasuhito
Shinkai, Tetsu
Tahara, Makoto
Kawada, Kenji
Ebi, Hiromichi
Sasaki, Yasutsuna
Jiang, Haiyi
Saijo, Nagahiro

November 2006

IntroductionZD6474 (vandetanib) is an orally available inhibitor of vascular endothelial growth fact...

lEarly Clinical Studies Group ofEORTC, 2EORTCData Center, ^Pierre Fabre Oncology, ^Centre Oscar Lambret, Lille, France Summary

September 2016

Background: Vinorelbine is an active drug in the treatment of lung and breast cancers and has a favo...

PHASE-I STUDY OF HIGH-DOSE EPIRUBICIN AND VINORELBINE IN PREVIOUSLY UNTREATED NON-SMALL-CELL LUNG-CANCER STAGE IIIB-IV

Bakker, M
Groen, HJM
Smit, EF
Smeets, J
Riggi, M
Postmus, Pieter

December 1995

The aim of the study was to determine the maximum tolerated dose (MTD) for the combination of high-d...

of Gemcitabine, LY2334737, in Human Tumor Xenografts

Efficacyof Low-doseoralmetronomicdosingof Theprodrug
Susan E. Pratt
Sara Durl
Robert L. Shepard
Gregory P. Donoho
James J. Starling
Enaksha R. Wickremsinhe
Everett J. Perkins
Anne H. Dantzig

September 2016

LY2334737, an oral prodrug of gemcitabine, is cleaved in vivo, releasing gemcitabine and valproic ac...

A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors.

Abstract

Extracted data

A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors.

Abstract

Extracted data

Related items

Related items